However, there are several strategies for the development of compounds that could inhibit NRF2 in cancer, including inhibitors of the NRF2-sMAF interaction and compounds with indirect impact on NRF2, including PI3K inhibitors and inhibitors of glutaminase (GLS) and glucose-6-phosphate dehydrogenase (G6PD) [14]. The gene discussed is NFE2L2; the disease is cancer.